# Immunotherapy Master Trial for Advanced Cancers

> **NCT07431073** · PHASE2 · NOT_YET_RECRUITING · sponsor: **UNICANCER** · enrollment: 275 (estimated)

## Conditions studied

- Advanced / Metastatic Solid Tumors
- Advanced Malignancy

## Interventions

- **DRUG:** METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each

## Key facts

- **NCT ID:** NCT07431073
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-06
- **Final completion:** 2034-01
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431073, "Immunotherapy Master Trial for Advanced Cancers". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT07431073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*